EMD Serono, USA
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Therapeutic Focus

Therapeutic Focus

EMD Serono's innovative research will drive the next wave of new therapies for patients with significant unmet needs.

Our research strategy builds upon a strong discovery phase portfolio from both internal research capabilities, as well as external business development opportunities. A network with alliances of other biotech companies and academic groups enriches our disease knowledge and technological capabilities fostering a constant flow of innovations into the organization.

Our research is focused on these areas:

Immuno-oncology is focused on harnessing the body’s own immune system to mount an immune response against cancer. Our immuno-oncology (iONC™) platform is comprised of three innovation clusters: therapeutic cancer vaccines, cancer stem cells, and tumor immunotolerance, each of which is focused on discovery research and the advancement of molecules into the clinic through proof of confidence.
> More about Immuno-Oncology
In order to optimize therapeutic success, we combine approaches that target the tumor cells and the tumor microenvironment. Innovative new molecules targeting the multi-faceted approach of the cancer disease process may also be suitable for use in combination with established standard cancer therapies. By using our established strengths in cancer pharmacology, signal transduction, and angiogenesis, we currently have several projects in our R&D pipeline aimed at addressing unmet needs in a range of cancers. For these approaches, we build upon expertise in both small molecules and biologics.
Our strength in biotherapeutics and immune-based therapies gives rich possibilities for novel therapeutic approaches in major areas of unmet medical needs. Our research focuses on drugs that modulate key pathogenic mechanisms in rheumatologic diseases. We combine approaches that target T- and B-cell biology, cytokines & chemokines pathways, as well as tissue biology / repair mechanisms. We currently have innovative projects in our R&D pipeline that may provide new therapies for diseases such as systemic lupuserythematosus (SLE), rheumatoid arthritis (RA), and osteoarthritis (OA).
> More about Immunology
Multiple Sclerosis
In order to develop new therapeutic options for patients, we conduct extensive research to expand our expertise in Multiple Sclerosis (MS). Our longstanding experience in MS provides a solid base upon which we build to study breakthrough solutions in other neurodegenerative diseases. Our strength in immunomodulation and neurobiology research gives a strong foothold into novel therapeutic approaches for improved symptomic treatment and for the development of disease modifying therapies.


Our dedication to improving the lives of patients can also be seen in the depth and breadth of our product portfolio.